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Left Ventricular Hypoplasia
A Spectrum of Disease Involving the
Left Ventricular Outflow Tract, Aortic Valve, and Aorta
Edward J. Hickey, MD,* Christopher A. Caldarone, MD,* Brian W. McCrindle, MD†
Toronto, Ontario, Canada
“Hypoplastic left heart syndrome” is an unsatisfactory term describing lethal underdevelopment of the left ventri-
cle (LV). It represents the more severe end of a spectrum of LV hypoplasia, mandating single-ventricle palliation
or cardiac transplantation. Less severe “borderline” ventricular hypoplasia may instead allow various biventricu-
lar therapeutic strategies and better long-term outcomes. In this review, we consider factors causing and modify-
ing the abnormal development of the LV. LV hypoplasia is typically seen in association with left ventricular out-
flow tract obstruction, itself part of a spectrum of related defects with common etiologies. Secondary responses
to outflow obstruction are complex but involve abnormal flow dynamics and shear stresses that result in com-
promised and poorly orchestrated ventricular growth and development. Subsequent remodeling is likely influ-
enced by genetic modifiers, including intrinsic myocardial growth signaling pathways, possibly including those of
HAND transcription factors. In addition, during the latter stages of gestation, cardiomyocytes undergo a switch in
myogenic potential and lose the ability to undergo mitosis. Ventricular hyperplasia can therefore no longer
occur; remodeling is instead limited to muscular hypertrophy. Subtle differences in this switch in myogenic
potential—and modulators thereof—are likely to be of clinical and therapeutic importance, especially in
children with “borderline LVs” being considered for fetal interventions or post-natal biventricular repair strat-
egies. Finally, by more clearly understanding the initiators and propagators of abnormal ventricular develop-
ment, we can hope to lean away from grouping a heterogeneous group of infants together under the unsat-
isfactory term “hypoplastic left heart syndrome.” (J Am Coll Cardiol 2012;59:S43–S54) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.04.046Left ventricular (LV) hypoplasia describes a lethal con-
genital heart abnormality that usually occurs in associa-
tion with obstruction to LV outflow. The degree of
hypoplasia is largely proportional to the severity of
obstruction except in particular circumstances where an
alternative exit for ventricular blood exists (e.g., a ven-
tricular septal defect). When hypoplasia is severe, the LV
is not capable of supporting the systemic circulation. In
this scenario, the only options for long-term survival
include neonatal cardiac transplantation or a sequence of
complex open-heart operations in infancy that lead to a
univentricular “Fontan” circulation in which the single
right ventricle supports the systemic circulation and
pulmonary blood flow is entirely passive. When hypopla-
sia is only mild, the LV may be capable of supporting the
systemic circulation once the outflow obstruction is
alleviated (biventricular repair). A large number of in-
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2011, accepted May 12, 2011.fants have moderate hypoplasia and therefore fall in a
grey zone; clinical decision-making regarding manage-
ment for these children with “borderline LVs” is a
considerable challenge.
Although LV hypoplasia encompasses a spectrum (Fig. 1),
the term “hypoplastic left heart syndrome” (HLHS) is
frequently used clinically to describe children with severe
hypoplasia. The majority of these children have nonpatent
outflow tracts (aortic atresia) and a rudimentary LV. For
infants with patent, but obstructed outflow, the term HLHS
becomes less satisfactory because ventricular hypoplasia may only
be mild or borderline. It is for these children with mild or
borderline hypoplasia that the pathogenetic mechanisms
underpinning LV hypoplasia become especially pertinent;
strategies to avert or reduce the development of hypoplasia
might allow a greater proportion of children to safely
undergo biventricular repair.
The purpose of this review is to: 1) describe important
candidate pathogenetic mechanisms that may represent
primary triggers leading to LV hypoplasia during em-
bryogenesis; 2) identify processes that may influence the
response of the developing LV to the primary triggers;
and 3) elaborate on the clinical difficulties in managing
the “borderline LV.”
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the Link With Coarctation
The majority of cases of LV hy-
poplasia occur in association with
downstream obstruction. Except
for a small minority of cases, the
level of maximal obstruction is at
the aortic annular region of the
left ventricular outflow tract
(LVOT) (1). In fact, in aortic
atresia—the most common manifestation of HLHS—the
LVOT is nonpatent at the valvar level. Therefore, it has
been suggested that LV hypoplasia is predominantly a
disease of the aortic valve (2). However, if LV hypoplasia is
predominantly a disease of aortic valve development, then
one might anticipate a genetic link between HLHS and
relatively minor anomalies such as simple bicuspid aortic
valve disease.
Evidence for such a link is emerging. Bicuspid aortic
valves are the most common cardiac abnormality found in
first-degree relatives of children with HLHS (3). In fact, the
incidence of bicuspid aortic valves has been reported as high
as 11% in otherwise normal first-degree relatives of HLHS
probands (2) (vs. 1% to 2% in the wider population).
Furthermore, case reports exist of monozygotic twins in
which 1 has HLHS (aortic atresia) and the other is
otherwise normal aside from a bicuspid aortic valve (4).
Lastly, genetic-linkage statistical analysis has very recently
provided evidence of shared chromosomal loci (10q22 and
6q23) in the etiology of bicuspid aortic valve disease and a
subset of children with HLHS (5).
Cushion defects and NOTCH. The precise mechanisms
underlying defective valvar development that result in out-
flow tract stenosis have not been clearly delineated. The
aortic valve is derived from endocardial cushions. A key
process in cushion formation is epithelial-to-mesenchymal
transformation, a process whereby epithelial cells lose their
polarity, detach from basement membrane, delaminate, and
migrate into the extracellular matrix with a mesenchymal
phenotype. These transformed mesenchymal cells are re-
sponsible for 2 key processes in early cushion formation:
1) they remodel the extracellular matrix; and 2) they form
the cellular constituents of the endocardial cushions. There-
fore, factors regulating endocardial cushion formation seem
attractive candidates for abnormal aortic valve and LVOT
development.
One such factor that is receiving considerable attention is
NOTCH (Fig. 2). NOTCH proteins are a family of 4
single-pass transmembrane proteins with extracellular li-
gand binding sites characterized by numerous epidermal
growth factor (EGF)-like repeats (6). Ligands for the
NOTCH receptor (Jagged1, Jagged2, and members of the
DSL family) interact with the EGF repeats. The DSL
family of ligands are themselves transmembrane proteins
Abbreviations
and Acronyms
HLHS  hypoplastic left
heart syndrome
LV  left ventricle/
ventricular
LVOT  left ventricular
outflow tract
Re  Reynold’s number(also with EGF repeats), and therefore, the DSL–NOTCHinteraction represents a form of close intercellular signaling.
Ligand–NOTCH interaction results in cleavage of the
NOTCH extracellular portion, close to the membrane. This
initial extracellular cleavage then triggers additional cleavage
of NOTCH by -secretase, at 2 sites within the membrane.
Ultimately, therefore, the intracellular portion of NOTCH
(NOTCH-ICD) is released and translocates to the nucleus.
Downstream transcriptional effects of NOTCH-ICD
include the activation of the transcription factor CSL (6).
CSL in the resting state is a transcriptional repressor—
partly due to its recruitment of other silencing factors.
Interaction with NOTCH-ICD causes CSL to be released
from its repressed state and instead activate transcription by
directly binding specific promoter sequences. The most
thoroughly investigated transcriptional targets for NOTCH1/
CSL-mediated signaling are Hey1 and Hey2, which encode
basic helix-loop-helix transcription factors. Other transcrip-
tional targets of NOTCH1-mediated signaling include
Cyclin D1, nodal, and Ephrin-B2, among others.
Double knockout of Hey1 and Hey2 results in severe
hypoplasia of major arterial structures (7), and evidence
suggests this may be a result of abnormal epithelial-to-
mesenchymal transformation within endocardial cushions.
Double mutations in Hey1 and a close functional relative
eyL result in both reduced numbers of mesenchymal
ushion cells and defective extracellular matrix processing
8)—the 2 key processes obligatory to normal endocardial
ushion formation. Double knockout Hey2/ results in
similar deficiencies, and NOTCH1/ null mutations com-
pletely abrogate epithelial-to-mesenchymal transformation
in endocardial cushions (8).
The link with aortic coarctation. Interestingly, Hey1 and
Hey2 are homologues of the zebrafish gene gridlock (grl).
Mutations in grl lead to major artery defects—particularly
tenosis at the junction of the 2 lateral dorsal aortae (Fig. 3)
9). In the zebrafish, this stenosis leads to absent caudal
lood flow. This zebrafish grl mutant phenotype bears an
eerie resemblance to human aortic coarctation. Aortic co-
arctation is a stenosis in the thoracic aorta usually occurring
immediately after the origin of the left subclavian artery in
the region of the ductus arteriosus. Each subclavian artery in
the human is an embryologic derivative of the seventh
intersegmental artery from the right and left dorsal aortae
immediately before the 2 fuse into a single common dorsal
aorta. Therefore, the zebrafish grl model may represent the
“coarctation phenotype” equivalent of human aortic coarc-
tation, thereby suggesting a causal relationship of Hey1 and
Hey2 to the disease in humans.
The NOTCH1/Hey coarctation hypothesis offers a po-
tential mechanism linking the well-known clinical associa-
tion between bicuspid aortic valve disease and aortic coarc-
tation. In fact, the molecular interplay underlying aortic
valve disease and aortic coarctation likely explains the
coexistence of HLHS in as many as 7% of neonates
S45JACC Vol. 59, No. 1, Suppl S, 2012 Hickey et al.
December 27, 2011/January 3, 2012:S43–S54 Left Ventricular HypoplasiaFigure 1 The Hypoplastic Left Ventricle Model
(1) A primary initiating event occurs that disrupts normal development of the outflow tract endocardial cushions. Cushion formation is coordinated by the influx of neural
crest (NC) cells. The NOTCH/Hey signaling axis appears to be important in epithelial-to-mesenchymal transformation within endocardial cushions and also plays impor-
tant roles in arch vessel development and the pathogenesis of coarctation. Finally, defects in genes involved in ventricular growth and differentiation (e.g., HAND and
T-box genes) might occasionally be primary initiators of left ventricular hypoplasia. (2) Abnormal left ventricular outflow tract (LVOT) development leads secondarily to
abnormal flow-dynamics and shear-stresses within the downstream developing ventricle. Ventricular growth is likely intricately related to signal transduction from such
mechanical forces. The secondary response of the developing ventricle to abnormal outflow tract development may also be modulated by variations in genes orchestrat-
ing ventricular growth (such as HAND proteins). Finally, the nature and timing of the “myogenic switch”—when myocytes lose their ability to proliferate—likely has impor-
tant implications for growth and remodeling of the left ventricle (LV) in the face of outflow tract obstruction. (3) Overall, it is the extent and nature of ventricular growth
and remodeling that will determine the function and morphology of the formed ventricle and where it sits on the spectrum of left ventricular hypoplasia. 1V  univentricu-
lar; 2V  biventricular; AV  aortic valve; RV  right ventricle.
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Left Ventricular Hypoplasia December 27, 2011/January 3, 2012:S43–S54presenting primarily with coarctation of the aorta (10). The
combination of mild, diffuse hypoplasia of the entire LVOT
and ventricle, with aortic coarctation—an entity recently
coined “hypoplastic left heart complex” (11)—could simi-
larly be explained by a NOTCH/Hey signaling aberration.
Finally, Shone complex (12)—an occasional manifestation
of HLHS due to multilevel stenoses involving the mitral
valve, aortic valve, supravalvular aorta, and coarctation—
Figure 2 Schematic Representation
of NOTCH-Mediated Signaling
NOTCH proteins are a family of transmembrane receptors. Once bound to their
ligands (members of the Jagged family and DSL ligands), the intracellular por-
tion (NOTCH-ICD) is cleaved by secretase and translocates to the nucleus.
Within the nucleus, NOTCH-ICD binds transcription factors, for example, CSL
leading to activation of promoters for genes including especially Hey1 and
Hey2, which themselves encode basic helix-loop-helix transcription factors.
Hey/ knockout animals exhibit severe hypoplasia of the ventricles and
defects in major vascular structures.
Figure 3 Impact of gridlock/ on Arterial Development in the
Mutants display atresia at the point of fusion of the 2 dorsal aortae. In humans, t
seventh segmental artery (later subclavian arteries), the site of aortic coarctation.could also be attributed to Hey family mutations disrupting
epithelial-to-mesenchymal transformation, endocardial
cushion formation, and large vessel stenoses analogous to
those seen in grl zebrafish mutants (13). Additionally,
OTCH1 in particular has been implicated in bicuspid
ortic valve disease and premature calcification of bicuspid
alves in adults (14).
ink with other gene and chromosomal defects. The
OTCH signaling axis presented in the preceding text is
ot the only candidate linking the interplay between LVOT
evelopment and ventricular hypoplasia. Turner syndrome
45,X0) is associated with bicuspid aortic valve disease,
oarctation, and aortic stenosis (15), suggesting a role for
hromosome X. In a large North American series of infants
ho all underwent Norwood (univentricular) operation for
LHS, Turner syndrome was the most common coexisting
enetic syndrome, and its presence was also associated with
ignificant decrements in survival (16). Such survival decre-
ents might conceivably relate to the strong link (17)
etween cardiovascular defects and fetal lymphedema in
urner syndrome. The association between Turner syndrome,
ortic valve disease, LV hypoplasia, and lymphedema is an
ntriguing one that warrants further attention.
Recently, genetic linkage studies have revealed other
hromosomal loci to be associated with left-sided outflow
ract lesions, including ventricular hypoplasia (18) (see
rossfeld et al. [19] for a useful summary). Microsatellite
enotyping among families harboring a spectrum of lesions
as now revealed linkage peaks corresponding to loci 16p12,
p23, and 10q21 in general, 10q22 and 6q23 linking
icuspid aortic valve and LV hypoplasia, and 2p15 specifi-
ally for HLHS (5,18).
afish
nt of fusion of the dorsal aortae occurs immediately beyond the
wild type. Reproduced, with permission, from Weinstein et al. (9).Zebr
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December 27, 2011/January 3, 2012:S43–S54 Left Ventricular HypoplasiaFinally, specific genes other than NOTCH have been
dentified as associated with a subset of patients with
LHS. These include genes encoding the cardiac gap
unction Connexin43 (GJA1) (20), an EGFR family tyrosine
inase receptor (ERBB4) (21), the cardiac transcription
actor NKX2.5 (NKX2.5/CSX) (22,23), and the HAND
roteins (24) (discussed in later text).
In summary, obstruction to left ventricular outflow at the
ortic valvar level is the predominant lesion found in infants
ith hypoplastic LVs. Chromosomal linkage analyses are now
uggesting familial links to exist between even mild aortic valve
nd outflow tract anomalies and HLHS, supporting a causal
elationship. Recently, molecular signaling pathways common to
ndocardial cushion development, large artery vasculogenesis,
nd ventricular hypoplasia have been identified. NOTCH- and
ey-mediated signaling defects likely compromise epithelial-to-
esenchymal transformation in endocardial cushions thereby
recipitating aortic valve defects, including severe stenosis in
ome. Similar mechanisms may underlie more diffuse stenotic
henotypes, multilevel stenoses (Shone complex), and aortic
oarctation. Additional gene products—including Connexin43,
yrosine kinase receptors, and NKX2.5, among others—are
nvolved in a subset of patients, implying pathogenetic hetero-
eneity.
rimary Hypoplastic Signals
lthough LV hypoplasia is often considered to be secondary
o outflow obstruction, the discovery of 2 basic helix-loop-
elix transcription factors—HAND-1 and HAND-2—that
ppear central to early ventricular development raises the
ossibility that in a minority of cases, the primary defect is
Figure 4 HAND-1 and HAND-2 Are Both Expressed in the Prima
Subsequently, expression becomes asymmetric in both the left–right axis and cran
ventricle. HAND-2 is instead located particularly in the bulbus cordis (developing ri
other abbreviations as in Figure 1. Reproduced, with permission, from Srivastavan the ventricle itself. Certainly, it is likely that they play
ome role in modulating the ventricular response to outflow
bstruction. Both HAND-1 and HAND-2 are coexpressed
niformly in the cardiac crescent of the primary heart field
25). During initial development of the heart tube, their
xpression is again fairly uniform, but marked differences in
xpression are then seen in the craniocaudal axis in a
entricle-specific fashion (25) (leading to left–right asym-
etry after looping) (Fig. 4). HAND-1 transcripts are
etected particularly in the conus arteriosus, truncus arteri-
sus, primitive atrium, and primitive ventricle, but expres-
ion is notably deficient in the bulbus cordis (the future right
entricle). Instead, HAND-2 is predominantly expressed in
he bulbus cordis. Experimental loss-of-function mutations
f HAND-2 are not compatible with life because of inade-
uate right ventricular development (26). The corollary was
herefore hypothesized that mutations in HAND-1 are
ssociated with LV hypoplasia and abnormalities in LVOT
evelopment. Indeed, early attempts to develop HAND-1–
ull mutant mice resulted in embryos that exhibited no
ttempt at rightward looping or development of a primitive
entricle. In addition, early embryonic death resulted from
ack of placental trophoblastic development (27). Elegant
ammalian studies involving mutations in HAND-1 and
AND-2 have since demonstrated that mutations in either
ead to a variety of serious defects in ventricular morpho-
enesis and that the impact of mutations among these 2
roteins are cumulative (Fig. 5) (28).
Recently, gene-sequencing studies have investigated the
ole of HAND mutations in human cardiac development
24). Among the Leipzig collection of human hearts with
art Field
dal axis. HAND-1 is expressed especially in the outflow tract and primitive
ntricle). A  primitive atrium; AS  aortic sac; CT  conotruncus; V  ventricles;ry He
iocau
ght ve
(25).
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Left Ventricular Hypoplasia December 27, 2011/January 3, 2012:S43–S54congenital defects, 31 had ventricular hypoplasia (24 left
and 7 right) in addition to a multitude of other coexisting
lesions. The HAND-1 gene sequence was amplified from
myocardial tissue from the hypoplastic ventricle from each
of these specimens and compared with the HAND-1 gene
sequence amplified from a normal human heart. In addition,
HAND-1 gene sequences were amplified from myocardial
tissue from the nonhypoplastic normal ventricle of the 31
experimental hearts. In 24 (77%) of the hypoplastic tissue
specimens, a common frame-shift mutation (A126fs) was
identified (24).
The A126fs mutation resulted in both an 9-kDa
fragment of the HAND-1 protein product and also a
2.5-fold reduction in mutant protein expression (perhaps
due to mRNA instability). The truncated mutant protein is
predicted to have only very sparse -helical content. In
functional experiments using luciferase reporter assays, the
A126fs mutant HAND-1 product was incapable of modu-
lating reporters containing D- and E-box transcriptional
control elements (24). These latter 2 elements are sequences
Figure 5 HAND-1 Null Mutants Exhibit Absence or Severely Hyp
(In Addition to Fatal Trophoblastic Defects)
HAND-2 null mutants exhibit severe hypoplasia of the developing right ventricle. Th
diac morphogenesis increased left to right. ba  branchial arch; KO  knockout;
temic (left) ventricle; other abbreviations as in Figures 1 and 5. Reproduced, withknown to be regulated by the HAND-1 protein (29). Nospecimen was homozygous for the A126fs mutation; con-
sistent with the observation in mice that homozygous
HAND-1/ null mutants died early in utero as a result of
placental insufficiency.
Interestingly, HAND-1 A126fs mutations were not re-
stricted to the hypoplastic ventricle. In 8 specimens, the
A126fs mutation was identified in the nonhypoplastic
ventricle in addition to the hypoplastic ventricle. This
observation is consistent with the notion that myocardial
progenitors within the primary heart field contribute to all
cardiac chambers and structures, whereas those from the
secondary heart field are more specific to particular regions
such as the outflow tract (30). If the origin of the A126fs
mutation occurred during proliferation of the primary heart
field, then the defect would be detected in all subsequent
primary heart field derivatives.
In summary, evidence is accumulating that suggests defects in
HAND-1 and -2 expression or function may play important
roles in left and right ventricular hypoplasia, respectively. First,
the 2 HAND proteins demonstrate differential expression in a
stia of the Developing Left Ventricle
act of mutations is cumulative. In the lower panel, the severity of abnormal car-
ateral mesoderm; lv  left ventricle; pv  pulmonic (right) ventricle; sv  sys-
sion, from McFadden et al. (28).opla
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December 27, 2011/January 3, 2012:S43–S54 Left Ventricular Hypoplasiadevelopment and cardiac looping. Second, loss-of-function mu-
tations result in nonviability due in part to lack of development
of the left and right ventricular precursors, respectively. Third,
gene-sequencing studies of human hearts affected by LV hypoplasia
have recently demonstrated loss-of-function mutations in
HAND-1 in a large proportion.
Flow Dynamics
Flow-streaming. The advent of fetal echocardiography has
allowed prenatal diagnosis and assessment of HLHS. Its use
has demonstrated LV hypoplasia to evolve in severity with
gestation (31,32). This clinical finding reflects the fact that
normal cardiac morphogenesis requires blood flow–directed
remodeling in addition to intrinsic patterning. Blood flow
remodeling describes the secondary development and dif-
ferentiation of structures as a direct result of shear stress and
flow dynamics of blood flow within them. This is not a new
concept; over 3 decades ago, the first model of hypoplastic
left heart was described and was achieved by temporarily
obliterating blood flow through the LV in 5-day-old chick
embryos (33). Twenty percent of the experimental group
survived, all displaying varying degrees of left-sided struc-
tural hypoplasia. The experiment led the authors to accu-
rately hypothesize that their model of “flow-volume hypoplasia”
was a result of abnormal “flow-volume streaming” (33).
Several experimental models have been developed to
investigate the impact of alterations in hemodynamic phys-
iology on cardiac development, including causing outflow
obstruction. Conotruncal banding causes mild-to-moderate
increases in ventricular afterload and precipitates cardiomyocyte
hyperplasia and hypertrophy, altered myosin chain gene
transcription profiles, increased contraction, and altered
myofiber orientation. However, the changes precipitated by
this model are all triggered predominantly by increases in
intraventricular pressure, which exerts a radial force perpen-
dicular to the flow of blood (34).
Shear stress. Shear stress instead describes a frictional force
acting along the endothelial surface parallel to the flow of
blood. Laminar blood flow begins to pass through the
human heart on day 24 of gestation, a couple of days after
early myocardial cell contraction (34). Flow characteristics
are frequently described by the Reynold’s number (Re): for
values 1, inertia forces within the fluid match those of the
fluid viscosity itself, and flow is therefore laminar. With
progressively higher Re values, inertia becomes increasingly
dominant, leading initially to localized laminar vortices
within the flow and subsequently—for Re 2,100—inertia
becomes so great that turbulent flow then occurs. In the
developing embryo, the Re of blood is very low, and flow is
predominantly laminar. The inner curvature of structures
therefore experiences the higher velocity of blood. Later in
gestation, the Re increases, and the outer curvatures expe-
rience the highest velocities of blood (or even turbulent
flow). However, despite laminar flow properties within early
embryonic cardiovascular structures, modern optical micro- flparticle velocimetry estimates the blood velocity in the
LVOT to be in the region of 26 mm/s—which corresponds
to wall shear stress comparable to that found in adult aortic
tissue (5 to 7 Pa).
In addition, shear stress is not uniform within developing
cardiac structures. According to Hagen-Poiseuille’s law of
volumetric flow, shear stress is inversely proportional to
luminal radius. Therefore, within the developing heart tube,
early sulci and expansions—followed by looping—result in a
complex and dynamic pattern of flow dynamics and shear
stresses. These forces act via various transmembrane signal
transduction proteins to affect intracellular mechanisms.
Candidate mechanoreceptors acting in this fashion include
integrins, tyrosine kinase, and G-protein–coupled receptors
and ion channels (34). Surface glycoprotein probably acts to
assist in shear stress sensing.
Signal transduction. Especially important in shear stress
signal transduction are believed to be ultrastructural mem-
brane cilia. For example, the prevailing hypothesis explain-
ing visceral handedness is that leftward flow of fluid across
the primitive node during the trilaminar disc stage causes
asymmetric (right-to-left) bending of motile cilia leading to
a polarized membrane with high left-sided calcium flux
(35). The left-sided calcium flux then leads to increased
local expression of the nodal gene; genetic asymmetry is
stablished and sidedness determined. In vascular structures,
ndothelial membrane cilia are an important interface
hrough which shear sensing is transduced. Downstream
ene expression is mediated via protein kinases and second
essenger systems. Important candidates for specific gene
argets include endothelin-1, nitric oxide synthase, and
rüppel-like factor-2 (36). Endothelin-1 acts as a vascular
nd cardiomyocyte growth factor (in addition to sustained
asoconstrictor), and its modulation in response to shear
tress is complex (34). However, endothelin-1 knockout
ertebrates display a range of complex cardiac malforma-
ions (37). The importance of Krüppel-like factor-2 (a zinc
nger transcription factor) is implied by direct induction in
esponse to elevated shear stress, particularly in large arterial
alls. Its loss of function leads to high-output cardiac failure
ndependent of anemia or structural defects (38). A role of
itric oxide synthase is appealing because nitric oxide
hysiologically antagonizes the effects of endothelin-1 and
rüppel-like factor-2 and has been shown to be induced by
hear stress in chick embryos (34).
In summary, signal transduction and gene modulation are
irectly affected by shear stresses mediated via cardiovascular
ndothelium. The precise regional and temporal patterns of
hese phenomena are undoubtedly complex, and the details
f interplay among candidate downstream transcription
ontrol elements and gene products have not been fully
lucidated. However, experimental manipulation of flow
hrough developing left-sided cardiac structures is known to
xert profound effects on left atrial, LV, and left atrioven-
ricular valve development. In the clinical setting, phasic
ow patterns are now known to be abnormal in the
S50 Hickey et al. JACC Vol. 59, No. 1, Suppl S, 2012
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In fact, even in the absence of other cardiac anomalies, early
closure of the foramen ovale in the first trimester (and
therefore markedly reduced left-sided blood flow) is be-
lieved to be an occasional cause of mitral atresia, aortic
atresia, and HLHS (40).
Restrictive atrial septum. Flow dynamics not only influ-
ence growth of left-sided cardiac structures, but may also be
important determinants of maturation of the pulmonary
vasculature. A small proportion of infants with HLHS have
an intact or restrictive atrial septum thereby impeding left
atrial and pulmonary venous egress. Their neonatal mortal-
ity is particularly high, even after successful atrial decom-
pression (41). Doppler studies reveal significant differences
in pulmonary venous phasic flow patterns in such infants
(39,42). These differences—in addition to pulmonary ve-
nous hypertension and profound postnatal cyanosis—may
be responsible for abnormalities in pulmonary maturation
that persist even after relief of atrial septal obstruction by
septostomy (43). Abnormalities in pulmonary maturation
might include venous “arterialization,” impaired vasoreac-
tivity, parenchymal abnormalities, and dilated lymphatics.
Interestingly, maternal hyperoxygenation has recently been
used to successfully identify infants with restrictive atrial
septa though impaired vasoreactivity (44). Pre-emptive
identification of such infants may in the future allow for
early noninvasive atrial septal defect enlargement through
novel techniques such as ultrasound histotripsy (45).
In summary, circumstantial evidence is strong to support the
notion that reduced or abnormal flow dynamics within the
developing LV (as a result of primary defects in the outflow
tract) contribute exigently to LV hypoplasia. The lesser degrees
of LV hypoplasia encountered in aortic atresia with ventric-
ular septal defect offer some proof of concept to the role of
flow dynamics in LV hypoplasia: the septal defect offers an
outflow to the LV cavity, thereby allowing through-flow
and promoting ventricular growth. Finally, altered flow
dynamics and left atrial egress probably modulate the
maturation of pulmonary vasculature, thereby impacting the
Figure 6 Schematic Representation of the Switch in Myogenic
Post-natal mammalian cardiomyocytes (C) are generally unable to replicate and th
ceivably, a fetus who receives therapeutic relief of outflow obstruction before the s
size and function to support a systemic circulation. Fetal interventions later in ges
growth.risk profile of neonatal treatment strategies.Remodeling: Hypoplasia Versus Hypertrophy
The developed human heart is capable of cardiomyocyte
hypertrophy, but not hyperplasia. In contrast, during em-
bryogenesis, cellular proliferation (hyperplasia) is an oblig-
atory requirement. Therefore, at some point during devel-
opment, ventricular muscle undergoes a switch in potential
from hyperplasia to hypertrophy. This switch in myogenic
potential may have important implications for ventricular
remodeling in neonates with left ventricular outflow ob-
struction. For example, the inability of a hypertrophied,
hypoplastic LV to undergo hyperplastic remodeling once
outflow obstruction is alleviated greatly compromises the
success of biventricular repair strategies in infants with a
borderline LV (Fig. 6).
In contrast to the typical hypertrophic response that
accompanies post-natal ventricular outflow obstruction,
aortic banding in fetal sheep mid-gestation leads to initial
cardiomyocyte hypertrophy, which is followed by a hyper-
plastic phase (46). Experimental right atrial clipping in first
trimester chick embryos leads to increased left-sided flow
and a hyperplastic ventricular growth response (47). Details
behind the switch from hyperplastic potential that occurs
later in gestation are unclear. In rats and sheep, it occurs
around—or shortly after—the time of birth (48), although
it may be earlier in humans (49). It is heralded in rats by a
final nuclear division without cytokinesis, therefore leading
to binucleation. However, the signal prompting this final
division is not known. Confusingly, identical cardiomyocyte
stimuli have been shown to trigger either cellular hypertro-
phy or hyperplasia in a time-dependent fashion. Angioten-
sin II, for example, is known to directly stimulate hypertro-
phy of post-natal hearts via the ERK mitogen–activated
protein kinase pathway. However, in late gestation, angio-
tensin II triggers hyperplasia—but not hypertrophy—via
the same ERK-signaling pathway (50). Presumably, there-
fore, different downstream steps, or additional modulators,
are responsible and have yet to be identified.
Interestingly, in normal individuals, subtle differences in
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diovascular health. Gestational weight (even within the
normal range) is one of the strongest independent predictors
of mortality from coronary atherosclerosis in later life (51).
Many “conventional” risk factors for atherosclerosis them-
selves appear to be strongly linked to gestational weight and
the environment in utero (52). One postulated mechanism
underlying this phenomenon is that exposure to intrauterine
stress and/or an earlier switch from hyperplasia leads to a
reduced absolute number of cardiomyocytes (52). An oth-
erwise normal ventricle with fewer cardiomyocytes will
exhibit cellular hypertrophy, and intercapillary distances
must be larger. The safety margin during times of myocar-
dial ischemia may therefore be less (52).
In summary, differences in cardiac remodeling may influence
the relative extent of hypertrophy and hyperplasia resulting from
other primary cardiovascular defects. After the switch from
hyperplastic potential, ventricular remodeling is hampered
by its ability to only undergo hypertrophy, rather than
growth. It is likely that the total number of cardiomyocytes
present at the time of the switch from hyperplasia to
hypertrophy will have implications for late function and
survival of infants subjected to biventricular repairs. With
the advent of fetal diagnosis of congenital heart lesions,
pharmacologic strategies to promote or prolong the period
of hyperplastic potential would be of real therapeutic value.
Finally, knowledge of the timing of loss of hyperplastic potential
will likely have important implications for the success and
durability of fetal interventional strategies aimed at alleviating
outflow obstruction.
Fetal Intervention
After initial reports in the early 1990s (53), transcatheter
fetal aortic valve dilation has become a viable therapeutic
option in certain centers (54). The aim of such intervention
is to avoid single-ventricle palliation by improving the
dimensions and performance of left-sided structures during
the latter stages of pregnancy. Balloon dilation of fetal aortic
stenosis has now been shown to result in enhanced aortic
(and mitral) valvular growth and improved LV function
(55). These favorable consequences appear to increase the
chances of successful post-natal biventricular physiology
(55), although comparisons to “controls” can be difficult.
Disappointingly, intervention for aortic stenosis even in the
second trimester has not been shown to improve growth and
development of LV dimensions (55). The reasons for this
are not obvious, but it may be that the window for
hyperplastic remodeling in humans is earlier than currently
feasible by conventional transcatheter techniques.
Irrespective of the lack of LV growth after fetal aortic
valvotomy, it appears that a certain group of fetuses within
the “grey zone” may be salvaged from univentricular phys-
iology. However, it is important to be able to more clearly
identify candidates likely to benefit from this risky technol-
ogy. Severe LV hypoplasia is unlikely to be salvaged.Therefore, potential candidates for fetal aortic valvotomy
include those with severe aortic stenosis in conjunction with
LV length within 80% of normal (z-score 2), aortic
valvular z-score diameters between 3.5 and 2 and flow
reversal in the transverse aortic arch (54). Future efforts to
more clearly define the timing and signals involved in loss of
hyperplastic remodeling may translate to fetal interventions
that lead to growth of LV dimensions that cross percentiles
towards normal.
The Management Conundrum
A challenging group of children with LVOT obstruction are
born with a LV that is neither rudimentary nor “near normal.”
These “borderline ventricles” of moderate hypoplasia represent
a clinical decision-management problem, because the decision
to pursue biventricular repair or univentricular repair must
frequently be made in the first few days of life. This decision is
difficult to reverse and may prove fatal if incorrect.
Intuitively, biventricular physiology is considered superior
to univentricular physiology. This notion has led to a clinical
bias favoring biventricular repairs in infants with borderline
LV hypoplasia (1,56). However, preferentially pursuing
biventricular repairs in infants with borderline hypoplasia
compromises aggregated survival, because many such in-
fants would actually have better predicted survival if instead
a Norwood (univentricular) repair had been pursued (1).
Reasons for this include the considerable complexity of
certain biventricular repair approaches (57), higher rates of
reintervention associated with biventricular repair (58), and
judgment error.
Long-term survival in the face of an inadequate systemic
pumping chamber seems incongruous. However, it has been
made a reality through 5 decades of research and surgical
evolution in areas of cardiopulmonary support, deep hypother-
mic circulatory arrest, cardiac reconstruction, systemic-
pulmonary shunt physiology, cavopulmonary shunt and single-
ventricle physiology, and neonatal intensive care medicine.
Consequently, since the first successful repairs of HLHS by
Dr. William Norwood in the early 1980s (59), late survival for
the (otherwise lethal) lesion are now in the region of 70%
(1,60) and as high as 90% in certain centers (61).
However, not everything is rosy. Univentricular repair of
nfants with hypoplastic LVs involves multiple-staged,
pen-heart operations, and families can expect the first few
ears to be punctuated with numerous lengthy admissions to
ertiary hospitals. The highest-risk initial “Norwood” oper-
tion is typically undertaken in the first couple of weeks of
ife, at an average patient weight of only 3 kg (1). It
involves a lengthy duration on cardiopulmonary support,
usually necessitating deep hypothermia and circulatory ar-
rest and therefore the potential for cerebral injury. Periop-
erative complications are common, and include emergent
repeat cardiac catheterizations and interventions (62), or
even need for salvage cardiac transplantation (1). Even late
after initial successes, right ventricular and tricuspid valve
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ations (63). Superimposed on cardiac morbidity is a high
incidence of neurological dysfunction: 20% of infants have
magnetic resonance imaging–detectable white matter le-
sions at birth (64), which increases to 50% after Norwood
operation. Gross spastic disabilities may be present in 5% to
10%, and subnormal intelligence quotients, behavioral prob-
lems, and delayed schooling are the norm in older children
(65). Recent efforts to limit exposure to cardiopulmonary
bypass and circulatory arrest during the neonatal period
through “hybrid” approaches are encouraging but—at present—
are associated with equally high mortality (66).
The paradox. The high morbidity associated with univen-
tricular repair (despite improving trends in overall mortality)
leads to a clinical paradox. The paradox is that although the
majority of physicians advise parents with prenatally diag-
nosed HLHS to continue pregnancy and then undergo
univentricular repair, the majority of the same physicians
would recommend termination of pregnancy if one of the
couple were a member of their own family (67)*. A cynic
would suggest that this paradox is driven by medical
self-fulfillment. The medical profession relishes challenges,
enjoys developing and experimenting novel therapies—and
they keep us in business: as much as a third of the entire
service of large pediatric cardiovascular divisions in North
America is related to treating LVOT obstruction, perform-
ing the multiple-staged, univentricular operations and deal-
ing with their complications. A more comfortable reason
behind the apparent discrepancy may be a greater under-
standing by physicians of the huge burden that all the
various aspects of treating a child with LV hypoplasia
imparts on the family unit (68). The discord between the
data we use to advise patients (mortality data) and our own
experiences of the morbidity suffered by patients and their
families that lead to discordant advice illustrates an impor-
tant gap in clinical understanding. As such, aggressive
efforts to lessen morbidity experienced by survivors and
improve their neurologic and functional performance should
be the next major objective for our specialty.
Summary
LV hypoplasia is a continuum of severity dependent on
numerous modifying factors (Fig. 1). It is typically seen in
association with LVOT obstruction, which is itself part of a
spectrum of related defects with common etiologies. The
secondary responses to outflow obstruction are complex but
involve abnormal flow dynamics and shear stresses, which
*At the Congenital Heart Surgeons’ Society annual meeting, Montreal 2004, an
audience of  100 congenital heart surgeons and cardiologists from North America
and Western Europe responded anonymously to the following question: what do you
advise a young couple receiving a diagnosis of HLHS at 14 weeks gestation during
their first pregnancy? Answer: termination of pregnancy 21%, compassionate care 6%,
Norwood operation 73%. The next question was: your daughter is the pregnant lady in
question; what do you advise? Answer: termination of pregnancy 67%, compassionate
care 5%, Norwood operation 26%, transplantation 1%.result in compromised and poorly orchestrated ventricular
growth and development. The remodeling process is the
crucial determinant of the morphological picture encoun-
tered at term gestation. Remodeling is likely influenced by
genetic modifiers, including intrinsic myocardial growth
signaling pathways, possibly including those of HAND
transcription factors. In addition, during the latter stages of
gestation, cardiomyocytes undergo a switch in myogenic
potential and lose the ability to undergo mitosis. Ventricular
hyperplasia can therefore no longer occur, and remodeling is
limited to muscular hypertrophy. Subtle differences in this
switch in myogenic potential—and modulators thereof—are
likely to be of clinical and therapeutic importance, especially
in children with “borderline LVs” (Fig. 1) being considered
for fetal interventions or post-natal biventricular repair
strategies. Finally, by more clearly understanding the initi-
ators and propagators of abnormal ventricular development,
we can hope to lean away from grouping a heterogeneous
group of infants together under the unsatisfactory term
“hypoplastic left heart syndrome.”
Reprint requests and correspondence: Dr. Edward J. Hickey,
The Hospital for Sick Children, 555 University Avenue, Toronto,
Ontario M5G 1X8, Canada. E-mail: edward.hickey@sickkids.ca.
REFERENCES
1. Hickey EJ, Caldarone CA, Blackstone EH, et al. Critical left ventric-
ular outflow tract obstruction: the disproportionate impact of biven-
tricular repair in borderline cases. J Thorac Cardiovasc Surg 2007;134:
1429–36, discussion 1436–7.
2. Hinton RB Jr., Martin LJ, Tabangin ME, Mazwi ML, Cripe LH,
Benson DW. Hypoplastic left heart syndrome is heritable. J Am Coll
Cardiol 2007;50:1590–5.
3. Brenner JI, Berg KA, Schneider DS, Clark EB, Boughman JA.
Cardiac malformations in relatives of infants with hypoplastic left-
heart syndrome. Am J Dis Child 1989;143:1492–4.
4. Mu TS, McAdams RM, Bush DM. A case of hypoplastic left heart
syndrome and bicuspid aortic valve in monochorionic twins. Pediatr
Cardiol 2005;26:884–5.
5. Hinton RB, Martin LJ, Rame-Gowda S, Tabangin ME, Cripe LH,
Benson DW. Hypoplastic left heart syndrome links to chromosomes
10q and 6q and is genetically related to bicuspid aortic valve. J Am Coll
Cardiol 2009;53:1065–71.
6. Niessen K, Karsan A. Notch signaling in the developing cardiovascular
system. Am J Physiol Cell Physiol 2007;293:C1–11.
7. Weismann CG, Gelb BD. The genetics of congenital heart disease: a
review of recent developments. Curr Opin Cardiol 2007;22:200–6.
8. Fischer A, Steidl C, Wagner TU, et al. Combined loss of Hey1 and
HeyL causes congenital heart defects because of impaired epithelial to
mesenchymal transition. Circ Res 2007;100:856–63.
9. Weinstein BM, Stemple DL, Driever W, Fishman MC. Gridlock, a
localized heritable vascular patterning defect in the zebrafish. Nat Med
1995;1:1143–7.
10. Quaegebeur JM, Jonas RA, Weinberg AD, Blackstone EH, Kirklin
JW. Outcomes in seriously ill neonates with coarctation of the aorta.
A multiinstitutional study. J Thorac Cardiovasc Surg 1994;108:841–
51, discussion 852–4.
11. Tchervenkov CI, Tahta SA, Jutras LC, Beland MJ. Biventricular
repair in neonates with hypoplastic left heart complex. Ann Thorac
Surg 1998;66:1350–7.
12. Shone JD, Sellers RD, Anderson RC, Adams P Jr., Lillehei CW,
Edwards JE. The developmental complex of “parachute mitral valve,”
supravalvular ring of left atrium, subaortic stenosis, and coarctation of
aorta. Am J Cardiol 1963;11:714–25.
33
3
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
5
5
5
5
6
S53JACC Vol. 59, No. 1, Suppl S, 2012 Hickey et al.
December 27, 2011/January 3, 2012:S43–S54 Left Ventricular Hypoplasia13. Zhong TP. Zebrafish genetics and formation of embryonic vascula-
ture. Curr Top Dev Biol 2005;71:53–81.
14. Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause
aortic valve disease. Nature 2005;437:270–4.
15. Sachdev V, Matura LA, Sidenko S, Ho VB, Arai AE, Rosing DR,
Bondy CA. Aortic valve disease in Turner syndrome. J Am Coll
Cardiol 2008;51:1904–9.
16. Patel A, Hickey EJ, Mavroudis C, et al. Impact of non-cardiac
congenital and genetic abnormalities on outcomes in hypoplastic left
heart syndrome. Ann Thor Surg 2010;89:1805–13, discussion 1813–4.
17. Loscalzo ML, Van PL, Ho VB, et al. Association between fetal
lymphedema and congenital cardiovascular defects in Turner syn-
drome. Pediatrics 2005;115:732–5.
18. Mcbride KL, Zender GA, Fitzgerald-Butt SM, et al. Linkage analysis
of left ventricular outflow tract malformations (aortic valve stenosis,
coarctation of the aorta, and hypoplastic left heart syndrome). Eur J
Hum Genet 2009;17:811–9.
19. Grossfeld P, Ye M, Harvey R. Hypoplastic left heart syndrome. J Am
Coll Cardiol 2009;53:1072–4.
20. Dasgupta C, Martinez AM, Zuppan CW, Shah MM, Bailey LL,
Fletcher WH. Identification of connexin43 (alpha1) gap junction gene
mutations in patients with hypoplastic left heart syndrome by dena-
turing gradient gel electrophoresis (DGGE). Mutat Res 2001;479:
173–86.
21. Mcbride KL, Zender GA, Fitzgerald-Butt SM, et al. Association of
common variants in ERBB4 with congenital left ventricular outflow
tract obstruction defects. Birth Defects Res A Clin Mol Teratol
2011;91:162–8.
22. Stallmeyer B, Fenge H, Nowak-Göttl U, Schulze-Bahr E. Mutational
spectrum in the cardiac transcription factor gene NKX2.5 (CSX)
associated with congenital heart disease. Clin Genet 2010;78:533–40.
23. Elliott DA, Kirk EP, Yeoh T, et al. Cardiac homeobox gene NKX2-5
mutations and congenital heart disease: associations with atrial septal
defect and hypoplastic left heart syndrome. J Am Coll Cardiol
2003;41:2072–6.
24. Reamon-Buettner SM, Ciribilli Y, Inga A, Borlak J. A loss-of-
function mutation in the binding domain of HAND1 predicts hy-
poplasia of the human hearts. Hum Mol Genet 2008;17:1397–405.
25. Srivastava D. HAND proteins: molecular mediators of cardiac devel-
opment and congenital heart disease. Trends Cardiovasc Med 1999;
9:11–8.
26. Srivastava D, Thomas T, Lin Q, Kirby ML, Brown D, Olson EN.
Regulation of cardiac mesodermal and neural crest development by the
bHLH transcription factor, dHAND. Nat Genet 1997;16:154–60.
27. Riley P, Anson-Cartwright L, Cross JC. The Hand1 bHLH tran-
scription factor is essential for placentation and cardiac morphogenesis.
Nat Genet 1998;18:271–5.
28. McFadden DG, Barbosa AC, Richardson JA, Schneider MD, Sriv-
astava D, Olson EN. The Hand1 and Hand2 transcription factors
regulate expansion of the embryonic cardiac ventricles in a gene
dosage-dependent manner. Development 2005;132:189–201.
29. Knofler M, Meinhardt G, Bauer S, et al. Human Hand1 basic
helix-loop-helix (bHLH) protein: extra-embryonic expression pattern,
interaction partners and identification of its transcriptional repressor
domains. Biochem J 2002;361:641–51.
30. Buckingham M, Meilhac S, Zaffran S. Building the mammalian heart
from two sources of myocardial cells. Nat Rev Genet 2005;6:826–835.
31. Hornberger LK, Need L, Benacerraf BR. Development of significant
left and right ventricular hypoplasia in the second and third trimester
fetus. J Ultrasound Med 1996;15:655–9.
32. Clark EB. Pathogenetic mechanisms of congenital cardiovascular
malformations revisited. Semin Perinatol 1996;20:465–72.
33. Harh JY, Paul MH, Gallen WJ, Friedberg DZ, Kaplan S. Experi-
mental production of hypoplastic left heart syndrome in the chick
embryo. Am J Cardiol 1973;31:51–6.
34. Groenendijk BC, Van der Heiden K, Hierck BP, Poelmann RE. The
role of shear stress on ET-1, KLF2, and NOS-3 expression in the
developing cardiovascular system of chicken embryos in a venous
ligation model. Physiology (Bethesda) 2007;22:380–9.
35. McGrath J, Somlo S, Makova S, Tian X, Brueckner M. Two
populations of node monocilia initiate left-right asymmetry in the
mouse. Cell 2003;114:61–73.
36. Groenendijk BC, Hierck BP, Gittenberger-De Groot AC, Poelmann
RE. Development-related changes in the expression of shear stressresponsive genes KLF-2, ET-1, and NOS-3 in the developing
cardiovascular system of chicken embryos. Dev Dyn 2004;230:57–68.
7. Groenendijk BC, Stekelenburg-de Vos S, Vennemann P, et al. The
endothelin-1 pathway and the development of cardiovascular defects in
the haemodynamically challenged chicken embryo. J Vasc Res 2008;
45:54–68.
8. Lee JS, Yu Q, Shin JT, et al. Klf2 is an essential regulator of vascular
hemodynamic forces in vivo. Dev Cell 2006;11:845–57.
9. Chintala K, Tian Z, Du W, Donaghue D, Rychik J. Fetal pulmonary
venous Doppler patterns in hypoplastic left heart syndrome: relation-
ship to atrial septal restriction. Heart 2008;94:1446–9.
0. Gardiner HM. Response of the fetal heart to changes in load: from
hyperplasia to heart failure. Heart 2005;91:871–3.
1. Rychik J, Szwast A, Natarajan S, et al. Perinatal and early surgical
outcome for the fetus with hypoplastic left heart syndrome: a 5-year
single institutional experience. Ultrasound Obstet Gynecol 2010;36:
465–70.
2. Taketazu M, Barrea C, Smallhorn JF, Wilson GJ, Hornberger LK.
Intrauterine pulmonary venous flow and restrictive foramen ovale in
fetal hypoplastic left heart syndrome. J Am Coll Cardiol 2004;43:
1902–7.
3. Vlahos AP. Hypoplastic left heart syndrome with intact or highly
restrictive atrial septum: outcome after neonatal transcatheter atrial
septostomy. Circulation 2004;109:2326–30.
4. Szwast A, Tian Z, Mccann M, Donaghue D, Rychik J. Vasoreactive
response to maternal hyperoxygenation in the fetus with hypoplastic
left heart syndrome. Circ Cardiovasc Imaging 2010;3:172–8.
5. Xu Z, Owens G, Gordon D, Cain C, Ludomirsky A. Noninvasive
creation of an atrial septal defect by histotripsy in a canine model.
Circulation 2010;121:742–9.
6. Samson F, Bonnet N, Heimburger M, et al. Left ventricular alterations
in a model of fetal left ventricular overload. Pediatr Res 2000;48:43–9.
7. deAlmeida A, McQuinn T, Sedmera D. Increased ventricular preload
is compensated by myocyte proliferation in normal and hypoplastic
fetal chick left ventricle. Circ Res 2007;100:1363–70.
8. Li F, Wang X, Capasso JM, Gerdes AM. Rapid transition of cardiac
myocytes from hyperplasia to hypertrophy during postnatal develop-
ment. J Mol Cell Cardiol 1996;28:1737–46.
9. Kim HD, Kim DJ, Lee IJ, Rah BJ, Sawa Y, Schaper J. Human fetal
heart development after mid-term: morphometry and ultrastructural
study. J Mol Cell Cardiol 1992;24:949–65.
0. Sundgren NC, Giraud GD, Stork PJ, Maylie JG, Thornburg KL.
Angiotensin II stimulates hyperplasia but not hypertrophy in imma-
ture ovine cardiomyocytes. J Physiol 2003;548:881–91.
1. Barker DJ. The origins of the developmental origins theory. J Intern
Med 2007;261:412–7.
2. Thornburg KL, Louey S. Fetal roots of cardiac disease. Heart 2005,
91:867–8.
3. Maxwell D, Allan L, Tynan MJ. Balloon dilatation of the aortic valve
in the fetus: a report of two cases. Br Heart J 1991;65:256–8.
4. McElhinney DB, Tworetzky W, Lock JE. Current status of fetal
cardiac intervention. Circulation 2010;121:1256–63.
5. McElhinney DB, Marshall AC, Wilkins-Haug LE, et al. Predictors of
technical success and postnatal biventricular outcome after in utero
aortic valvuloplasty for aortic stenosis with evolving hypoplastic left
heart syndrome. Circulation 2009;120:1482–90.
6. Lofland GK, McCrindle BW, Williams WG, et al., for the Congen-
ital Heart Surgeons Society. Critical aortic stenosis in the neonate: a
multi-institutional study of management, outcomes, and risk factors.
J Thorac Cardiovasc Surg 2001;121:10–27.
7. Hickey EJ, Yeh T Jr., Jacobs JP, et al. Ross and Yasui operations for
“complex” biventricular repair in infants with critical left ventricular
outflow tract obstruction. Eur J Cardiothorac Surg 2010;37:279–88.
8. Hickey EJ, Caldarone CA, Blackstone EH, et al. Biventricular repair
of critical aortic stenosis: the high mortality associated with early
re-intervention. J Thorac Cardiovasc Surg 2012. In press.
9. Norwood WI, Kirklin JK, Sanders SP. Hypoplastic left heart
syndrome: experience with palliative surgery. Am J Cardiol 1980;
45:87–91.
0. Ohye RG, Sleeper LA, Mahony L, et al. Comparison of shunt types
in the Norwood procedure for single-ventricle lesions. N Engl J Med
2010;362:1980–92.
66
6
S54 Hickey et al. JACC Vol. 59, No. 1, Suppl S, 2012
Left Ventricular Hypoplasia December 27, 2011/January 3, 2012:S43–S5461. Ghanayem NS, Hoffman GM, Mussatto KA, et al. Perioperative
monitoring in high-risk infants after stage 1 palliation of univentricular
congenital heart disease. J Thorac Cardiovasc Surg 140:857–63.
62. Hickey EJ, Asoh K, McCrindle BW, Elmi M, Van Arsdell GS,
Benson L. Characterizing the risk of cardiac catheterization early after
Norwood operation: would operative assessment in a hybrid suite be of
value. Paper presented at: Canadian Cardiac Congress 2008; October
27, 2008; Toronto, Ontario, Canada.
63. Elmi M, Hickey EJ, Williams WG, Van Arsdell G, Caldarone CA,
McCrindle BW. Long-term tricuspid valve function after Norwood
operation. J Thorac Cardiovasc Surg 2011;142:1341–7.
64. Galli KK, Zimmerman RA, Jarvik GP, et al. Periventricular leukoma-
lacia is common after neonatal cardiac surgery. J Thorac Cardiovasc
Surg 2004;127:692–704.
65. Hickey EJ, Karamlou T, Ungerleider RM. Brain injury following
infant cardiac surgery and neuroprotective strategies. In: Gravlee GP,
Davis RF, Stammers AH, Ungerleider M, editors. CardiopulmonaryBypass: Principles and Practice. 3rd edition. Philadelphia, PA:
Lippincott Williams & Williams, 2007:710–34.
6. Honjo O, Benson LN, Mewhort HE, et al. Clinical outcomes,
program evolution, and pulmonary artery growth in single ventricle
palliation using hybrid and Norwood palliative strategies. Ann Thorac
Surg 2009;87:1885–92, discussion 1892–3.
7. Jacobs JP, Ungerleider RM, Tchervenkov CI, et al. Opinions from the
audience response survey at the first joint meeting of the Congenital
Heart Surgeons’ Society and the European Congenital Heart Surgeons
Association. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu
2005;8:198–217.
8. Menahem S, Grimwade J. Pregnancy termination following prenatal
diagnosis of serious heart disease in the fetus. Early Hum Dev
2003;73:71–8.Key Words: borderline left ventricle y embryology y fetal y hypoplastic
left heart syndrome y left ventricular hypoplasia.
